Urological Cancer Treatment — Cost, Top Hospitals & Success Rates | MyMedicPlus

Urological cancers encompass malignant tumours arising from the kidneys, ureters, bladder, urethra, prostate, testes, and penis. Collectively they represent some of the most common and most treatable cancers in men, as well as some of the most aggressive. Prostate cancer is the most frequently diagnosed non-cutaneous cancer in men globally — 1.4 million new cases and 375,000 deaths annually — with a clinical spectrum ranging from slow-growing localised disease managed by active surveillance to rapidly fatal metastatic castration-resistant cancer. Renal cell carcinoma (RCC) — kidney cancer — is the 13th most common malignancy globally, with approximately 430,000 new cases per year. The majority are clear cell RCC, increasingly detected incidentally on cross-sectional imaging (CT or MRI performed for other indications). Bladder cancer (predominantly urothelial carcinoma) is the 10th most common cancer worldwide, with the highest recurrence rate of any solid tumour — surveillance after TURBT is mandatory for life. Testicular germ cell tumours (GCTs) are the most common malignancy in men aged 15–35 and the most curable solid cancer — 5-year overall survival exceeds 95% due to exceptional chemotherapy sensitivity. Penile cancer is rare in high-income countries (incidence 1 per 100,000) but remains a significant cause of morbidity in Sub-Saharan Africa, South America, and Southeast Asia, where HPV infection and inadequate circumcision are major risk factors. Upper tract urothelial carcinoma (UTUC — renal pelvis and ureter) shares the same urothelial origin as bladder cancer but is rarer and managed by nephroureterectomy. Effective oncological management of urological cancers requires multidisciplinary tumour board review, accurate molecular and genetic profiling, and individualised shared decision-making combining surgery, radiation, and increasingly potent systemic agents.

Prostate cancer staging: low-risk (PSA below 10, Gleason grade group 1–2, cT1–T2a) — active surveillance or curative treatment; intermediate-risk (PSA 10–20, GGG 2–3, cT2b–T2c) — curative treatment (surgery or radiation); high-risk/locally advanced (PSA above 20, GGG 4–5, cT3–T4) — multimodality with ADT and radiation or surgery; metastatic hormone-sensitive (mHSPC) — ADT intensification with docetaxel or novel AR pathway inhibitors; castration-resistant (mCRPC) — sequential systemic therapy. Renal cell carcinoma staging by TNM: T1a (below 4 cm, confined to kidney) — active surveillance or ablation for small tumours; T1b–T2 (4–10 cm, confined) — partial or radical nephrectomy; T3–T4 (perinephric fat, venous invasion, adjacent organs) — radical nephrectomy; M1 metastatic — systemic therapy. Bladder cancer: non-muscle-invasive (Ta, T1, CIS) — TURBT with intravesical BCG or chemotherapy; muscle-invasive (T2–T4) — neoadjuvant chemotherapy plus radical cystectomy or bladder-preserving trimodality therapy; metastatic — immunotherapy/chemotherapy combination. Testicular GCT: classified seminoma vs NSGCT; Stage I (confined to testis) — radical orchiectomy plus surveillance/adjuvant therapy; Stage II (retroperitoneal nodes) — BEP chemotherapy or RPLND; Stage III (distant metastases) — BEP (3 cycles good-risk; 4 cycles poor-risk). Renal pelvis/ureter UTUC: managed by laparoscopic or robotic nephroureterectomy (removal of kidney plus full ureter plus bladder cuff) with neoadjuvant cisplatin-based chemotherapy for muscle-invasive UTUC.

Urological cancer management begins with accurate staging to define local extent, nodal involvement, and distant metastasis. CT chest, abdomen, and pelvis is the standard cross-sectional staging modality. MRI pelvis provides superior soft tissue detail for prostate cancer local staging (extracapsular extension, seminal vesicle invasion), bladder cancer, and penile cancer. PSMA PET-CT has transformed prostate cancer staging — detecting nodal and bone disease at PSA levels of 0.2 ng/mL and identifying PSMA-expressing tumour for targeted radioligand therapy eligibility (lutetium-177 PSMA). FDG PET-CT is standard for testicular cancer restaging and renal cell carcinoma staging in selected cases. Molecular biomarkers guide systemic therapy eligibility: PD-L1 expression (CPS score) for immunotherapy in bladder and renal cancer; BRCA1/2 and HRR gene mutations for PARP inhibitor eligibility in prostate cancer (olaparib, rucaparib); FGFR3 mutations for erdafitinib in bladder cancer; VHL mutation and VEGF pathway activation in clear cell RCC for VEGF-targeted therapy (sunitinib, pazopanib, axitinib, cabozantinib). Performance status (ECOG 0–2) gates eligibility for aggressive surgical and chemotherapy approaches. Cisplatin eligibility (GFR above 50–60 mL/min, ECOG 0–1, no peripheral neuropathy) determines whether platinum-based chemotherapy (BEP for testicular; GC or MVAC for bladder/UTUC) can be administered safely.

Prostate cancer: active surveillance for low-risk disease; radical prostatectomy (RARP or open) for localised disease; external beam radiotherapy (IMRT/IGRT, SBRT) or brachytherapy (LDR seeds, HDR boost) for localised to locally advanced disease; ADT with abiraterone, enzalutamide, apalutamide, or darolutamide for metastatic hormone-sensitive disease; lutetium-177 PSMA-617 (Pluvicto) for PSMA-positive mCRPC; olaparib/rucaparib for BRCA-mutated mCRPC. Renal cell carcinoma: partial nephrectomy (robot-assisted RAPN, laparoscopic, or open) for T1a–T1b — nephron preservation reduces chronic kidney disease progression; radical nephrectomy for T2–T4 with or without inferior vena cava thrombectomy for tumour thrombus extension; percutaneous ablation (cryoablation, RFA) for T1a under 4 cm in surgical high-risk patients; checkpoint inhibitor combinations (nivolumab plus ipilimumab; pembrolizumab plus axitinib) for first-line intermediate/poor-risk metastatic clear cell RCC (CheckMate 214, KEYNOTE-426 trials); cabozantinib or sunitinib for favourable risk; lenvatinib plus everolimus or nivolumab for second-line. Bladder cancer: TURBT with BCG for NMIBC; neoadjuvant GC plus radical cystectomy with urinary diversion for MIBC; enfortumab vedotin plus pembrolizumab for first-line cisplatin-ineligible advanced urothelial carcinoma (EV-302 trial). Testicular GCT: radical orchiectomy plus stage-specific chemotherapy (BEP) or surveillance; RPLND for residual retroperitoneal masses after chemotherapy; high-dose chemotherapy with ASCT for relapsed disease. For upper tract urothelial carcinoma (UTUC), radical nephroureterectomy — laparoscopic or robot-assisted, with excision of the ipsilateral bladder cuff — is the oncological standard. Neoadjuvant cisplatin-based chemotherapy improves survival for muscle-invasive UTUC where cisplatin is feasible before surgery.

Prostate cancer — low-risk disease: 15-year cancer-specific survival above 97% regardless of management modality (ProtecT trial, 2023). Metastatic hormone-sensitive prostate cancer: ADT plus novel AR inhibitor combinations (ENZAMET, LATITUDE, TITAN, ARCHES trials) improve 5-year overall survival from approximately 40% to 55–65%, representing a landmark advance. Lutetium-PSMA-617 extends overall survival in PSMA-positive mCRPC by 4 months (VISION trial); THE-RA-P trial showed superior results versus cabazitaxel in chemotherapy-eligible patients. Renal cell carcinoma — localised T1a: partial nephrectomy achieves 5-year cancer-specific survival above 95%. Metastatic RCC: nivolumab plus ipilimumab (CheckMate 214) improves 5-year overall survival to 42% versus 26% for sunitinib for intermediate/poor-risk disease — a transformative improvement. Bladder cancer: enfortumab vedotin plus pembrolizumab (EV-302) achieved median overall survival of 31.5 months versus 16.1 months for chemotherapy in cisplatin-ineligible advanced urothelial carcinoma — now the first-line standard. Testicular cancer: BEP chemotherapy for metastatic disease achieves 5-year overall survival of 95% (good prognosis), 89% (intermediate), and 71% (poor prognosis) — making testicular cancer the most curable solid tumour in oncology. Surveillance with active monitoring after stage I orchiectomy avoids 70–80% of men any additional treatment while curing those who relapse on salvage chemotherapy.

Radical prostatectomy: urinary incontinence (10–30% at 12 months, most recovering by 24 months), erectile dysfunction (40–70% depending on nerve-sparing), anastomotic stricture, and lymphocele. Radiotherapy: radiation proctopathy (5–8% late), cystitis, erectile dysfunction developing progressively over 2–3 years. ADT: hot flushes, osteoporosis (bisphosphonate or denosumab required), metabolic syndrome, cognitive impairment, and cardiovascular disease acceleration. Novel AR inhibitors add fatigue, falls, cognitive effects (enzalutamide), and cardiovascular risk (abiraterone — corticosteroid coverage required). Radical nephrectomy: loss of a kidney (reducing GFR by 30–40%), adrenal insufficiency if adrenalectomy performed, pneumothorax for upper pole tumours, and ileus. Partial nephrectomy: urinary leak (fistula) from collecting system entry (2–5%), haematoma, and arteriovenous fistula. Sunitinib and pazopanib (VEGF TKI): hypertension (>60%), hand-foot syndrome, fatigue, hypothyroidism, hepatotoxicity, and diarrhoea. Checkpoint inhibitor combinations (nivolumab + ipilimumab): immune-related adverse events — colitis (20–30%), pneumonitis (5–10%), hepatitis, endocrinopathies — requiring systemic corticosteroids for grade 3–4 toxicity. BEP chemotherapy for testicular cancer: bleomycin pulmonary toxicity (dose-limiting cumulative pulmonary fibrosis), cisplatin nephrotoxicity, neurotoxicity, ototoxicity, azoospermia (sperm banking mandatory before treatment), and long-term cardiovascular risk. Radical cystectomy: 30-day major morbidity 25–30%; urinary diversion complications (ureteroenteric anastomotic leaks, metabolic acidosis from ileal conduit); sexual dysfunction in majority.

Prostate cancer: PSA every 3–6 months for 2 years post-treatment, then 6-monthly to 5 years, then annually. After radical prostatectomy, PSA should be undetectable (below 0.1 ng/mL); biochemical recurrence (two PSA above 0.2 ng/mL) triggers PSMA PET-CT and consideration of salvage radiotherapy. After radiotherapy, PSA nadir plus 2 ng/mL (Phoenix definition) defines biochemical failure. After ADT, testosterone and PSA every 3–6 months; bone density annually; PSMA PET-CT when PSA rises on castrate therapy. RCC: CT chest, abdomen, pelvis per risk-stratified protocol — every 6 months for 2 years then annually for intermediate/high-risk disease; annually for low-risk T1a. eGFR monitoring after nephrectomy (partial or radical) at regular intervals. Bladder cancer: cystoscopy every 3 months for 2 years (high-risk NMIBC), then 6-monthly; CT urogram annually for high-risk disease; after cystectomy, CT imaging every 6 months for 2 years. Testicular cancer: clinical exam, tumour markers, and CT every 3–4 months for 2 years on surveillance; stage-specific intensification thereafter. Monthly self-examination of remaining testis for second primary cancer detection. Penile cancer: clinical examination of primary site and inguinal lymph nodes every 3 months for 2 years, then 6-monthly. Long-term survivorship care for all urological cancer patients should include cardiovascular risk management, bone health, sexual health rehabilitation, and psychological support.

Prostate cancer: RARP India USD 6,000–15,000; USA USD 25,000–60,000. EBRT (radiotherapy): India USD 5,000–15,000; USA USD 25,000–80,000. ADT (LHRH agonist monthly): India USD 100–300; USA USD 1,000–2,000. Enzalutamide/abiraterone monthly: India USD 500–2,500 (generic access); USA USD 5,000–12,000. Lutetium-PSMA (per cycle, 6 cycles): India USD 4,000–8,000; USA USD 20,000–42,000. Kidney cancer: robotic partial nephrectomy India USD 5,000–12,000; USA USD 20,000–50,000. Sunitinib monthly: India USD 500–2,000 (generic); USA USD 8,000–15,000. Nivolumab+ipilimumab (per cycle): India USD 3,000–8,000 (access programs); USA USD 15,000–30,000. Bladder cancer: TURBT India USD 800–2,500; USA USD 5,000–15,000. BCG intravesical (6 courses): India USD 200–800; USA USD 1,000–3,000. Radical cystectomy: India USD 6,000–15,000; USA USD 40,000–100,000. Enfortumab vedotin + pembrolizumab (monthly): USA USD 20,000–35,000; access in India through clinical trials. Testicular cancer: radical orchiectomy India USD 1,500–4,000. BEP chemotherapy (3 cycles): India USD 2,000–5,000; USA USD 20,000–50,000. Medical tourism to India, Thailand, and Turkey provides major cost savings (60–85% versus USA) for surgery and chemotherapy, with equivalent JCI-accredited oncology expertise at Tata Memorial, Apollo, Fortis, and Manipal Hospitals.

Active surveillance represents a major alternative to immediate treatment for low-risk prostate and early renal cancers, avoiding treatment toxicity without compromising cancer-specific survival. Focal therapy (HIFU, cryotherapy, photodynamic therapy) offers intermediate options between surveillance and whole-gland treatment for low- to intermediate-risk localised prostate cancer. Percutaneous thermal ablation (cryoablation, radiofrequency, microwave ablation) under CT or ultrasound guidance provides surgical alternatives for renal tumours under 4 cm in patients unfit for nephrectomy. Stereotactic ablative body radiotherapy (SABR/SBRT) delivers high-dose focal radiation to small metastatic deposits (oligometastatic prostate, RCC, or bladder cancer) in 1–5 sessions, potentially extending progression-free survival in oligometastatic disease. PSMA-targeted alpha therapy (actinium-225 PSMA-617) is in clinical trials for mCRPC, offering potentially superior tumour kill versus beta-emitting lutetium-177. Tumour-infiltrating lymphocyte (TIL) therapy and CAR-T cell therapy are investigational in urological cancers. Organ preservation strategies for bladder cancer (trimodality therapy — TMT) preserve the native bladder in 40–50% of MIBC patients with comparable survival to radical cystectomy in carefully selected cases. Chemohyperthermia — intravesical hyperthermic mitomycin C (HIVEC) — improves drug penetration for NMIBC, achieving higher complete response rates than standard intravesical therapy in BCG-unresponsive or intermediate-risk disease.